Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.



     Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

Patent coverage granted until 2031 for Trevena's lead Phase 2 compound in
acute heart failure

PR Newswire

KING OF PRUSSIA, Pa., July 17, 2013

KING OF PRUSSIA, Pa., July 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a
clinical stage pharmaceutical company and the leader in the discovery and
development of G-protein coupled receptor (GPCR) biased ligands, announced
today that the United States Patent and Trademark Office has granted Trevena a
composition of matter patent covering its development product TRV027.  United
States Patent No. 8,486,885 entitled "Beta-Arrestin Effectors and Composition
and Methods of Use Thereof," is expected to provide coverage for TRV027 until
at least July 2031.    

TRV027 is an experimental intravenous drug for the treatment of acute
decompensated heart failure (ADHF), currently in mid-stage clinical trials.
 It is a novel beta-arrestin biased ligand of the angiotensin II type 1
receptor that combines the proven benefits of angiotensin blockade with new
beta-arrestin-mediated biology to preserve cardiac and renal function. 
Trevena recently entered into a collaborative licensing option agreement for
the development of TRV027 with Forest Laboratories Inc. (NYSE:FRX).  The
company expects to commence a 500-patient multi-center Phase 2b clinical trial
for TRV027 in ADHF patients by year end.

"This core patent provides the foundation for broad and enforceable
intellectual property protection for TRV027, and is followed by a series of
patent applications made by Trevena to protect our growing pipeline of GPCR
biased ligands in key markets around the world,"  said Maxine Gowen, Trevena's
President and Chief Executive Officer.  David Solomon, Forest's SVP of
Corporate Development & Strategic Planning, and a Board member at Trevena,
added, "This issued patent enhances the value potential of TRV027, and
provides an essential platform from which to drive its commercialization."  

Trevena recently presented the results of a Phase 2a study on the hemodynamic
effects of TRV027 in patients with advanced heart failure with reduced
ejection fraction (NCT01187836), as a poster at the American College of
Cardiology meeting in March 2013. The Phase 2a trial was an ascending dose
titration study in patients with stable NYHA Class 3 or 4 heart failure.   

About ADHF
The American Heart Association estimates that ADHF hospitalization costs the
U.S. healthcare system more than $20 billion each year in direct spending.
 ADHF is already the leading reason for hospitalization of individuals over 65
years old in the United States, with more than 1 million hospital admissions
per year.  ADHF is also the most costly diagnosis for Medicare in the nation.
 Despite the significance of this problem, current therapies are not producing
meaningful improvements in patient outcomes.  ADHF incidence is increasing
globally, and both heart failure mortality and hospital re-admission following
an ADHF event remain extremely high.

About Trevena
Trevena, Inc. is a clinical stage pharmaceutical company focused on
discovering and developing the next generation of GPCR targeted medicines.
 GPCRs are the targets for at least one-third of modern medicinal products,
and remain the predominant class of targets under clinical evaluation.
 Trevena's expertise lies in engineering "biased ligands" that activate only
the beneficial signaling pathways downstream of a GPCR to unlock new biology
and avoid drug adverse effects.  In addition to TRV027, Trevena's pipeline
currently includes a clinical stage mu-opioid biased ligand for post-operative
pain, and earlier-stage programs for chronic pain, and Parkinson's disease.
 For more details, visit www.Trevenainc.com.

About Forest Laboratories
Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal
and pain management medicine.  Forest's pipeline, the most robust in its
history, includes product candidates in all stages of development across a
wide range of therapeutic areas.  The Company is headquartered in New York,
NY.  To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings.  Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.

For more information, please contact:
Rosamond Deegan, Vice President, Business Development 610-354-8840 x225
(Corporate Inquiries)
Kimberly Minarovich, Christensen, 917-533-3268 (Media Inquiries)

SOURCE Trevena, Inc.

Website: http://www.Trevenainc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement